It is the cache of ${baseHref}. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

Critical appraisal of the role of everolimus in advanced neuroendocrin
skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

14887

Critical appraisal of the role of everolimus in advanced neuroendocrine tumors of pancreatic origin



Review

(2253) Total Article Views


Authors: Mulet-Margalef N, Capdevila J

Published Date September 2012 Volume 2012:2 Pages 29 - 37
DOI: http://dx.doi.org/10.2147/GICTT.S24826

Received: 20 June 2012
Accepted: 25 July 2012
Published: 27 September 2012
Núria Mulet-Margalef, Jaume Capdevila

Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain

Abstract: For many years, the treatment of advanced pancreatic neuroendocrine tumors (pNETs) has been limited almost entirely to somatostatin analogs and streptozocin-based chemotherapy, with modest benefit. Increasing knowledge of the biologic features of pNETs has allowed the design of molecular-based clinical trials, which have taken a step forward in the management of these tumors. In this review, we discuss the molecular rationale for the development of everolimus for patients with advanced pNETs, critically review the clinical data obtained by the main studies in this setting, and discuss essential considerations based on recent findings in pNET biology for future drug development involving the phosphatidylinositol 3' kinase-AKT-mTOR pathway.

Keywords: pancreatic neuroendocrine tumors, everolimus, targeted therapies


Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read: